



# **Felodipine**

# **Extended-Release Tablets USP Assay**





Notes: Felodipine is a calcium channel blocker and acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. Felodipine prevents myocyte contraction by binding to calcium-binding proteins, which exhibits competitive antagonism of the mineralcorticoid receptor. This event results into inhibiting the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase and blocking calcium influx through voltage-gated T-type calcium channels. This reduces movement of calcium into the cells of the heart and blood vessels and increases supply of blood and oxygen to the heart.

#### **Method Conditions**

Column: Cogent RP C18™, 5µm, 100Å

Catalog No.: 68518-15P

Dimensions: 4.6 x 150 mm

Buffer: 6.9 mg/mL of monobasic sodium phosphate in water. Adjust

with 1 M phosphoric acid to a pH of  $3.0 \pm 0.05$ 

Mobile Phase: Acetonitrile, methanol, and Buffer (40:20:40)

Injection vol.: 40µL Flow rate: 1.0 mL/min Detection: 362 nm

Standard solution: 0.02 mg/mL of USP Felodipine in Mobile phase

Peak: 1. Felodipine

### **Discussion**

This method demonstrates the USP Felodipine Extended-Release Tablet assay in the Cogent RP C18. As shown in the chromatogram with a five injection overlay, the peak efficiency is superb and USP peak tailing guidelines are easily met with the Cogent RP C18™ column. This demonstrates a great alternative column for easy plug and play methods. The Cogent C18 is end-capped and has excellent reproducibility and robustness.

## Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 43(6)

Page Information: USP43-NF38 - 1827 USP42-NF37 - 1787 USP41-NF36 - 1690

